drug
as of 2026-07-01JNJ-37822681
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Johnson & Johnson
2 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
2
An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia
NCT00728195Phase 2Completed
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication
indication
indication